These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15646069)

  • 1. A new prospective against HIV infection: induction of murin CCR5-downregulating antibodies.
    Barassi C; Marenzi C; Pastori C; Longhi R; Lazzarin A; Lopalco L
    New Microbiol; 2004 Apr; 27(2 Suppl 1):85-94. PubMed ID: 15646069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy.
    Barassi C; Soprana E; Pastori C; Longhi R; Buratti E; Lillo F; Marenzi C; Lazzarin A; Siccardi AG; Lopalco L
    J Virol; 2005 Jun; 79(11):6848-58. PubMed ID: 15890924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells.
    Bomsel M; Pastori C; Tudor D; Alberti C; Garcia S; Ferrari D; Lazzarin A; Lopalco L
    AIDS; 2007 Jan; 21(1):13-22. PubMed ID: 17148963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IFN-gamma and IL-12 differentially regulate CC-chemokine secretion and CCR5 expression in human T lymphocytes.
    Losana G; Bovolenta C; Rigamonti L; Borghi I; Altare F; Jouanguy E; Forni G; Casanova JL; Sherry B; Mengozzi M; Trinchieri G; Poli G; Gerosa F; Novelli F
    J Leukoc Biol; 2002 Oct; 72(4):735-42. PubMed ID: 12377943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery.
    Swan CH; Bühler B; Steinberger P; Tschan MP; Barbas CF; Torbett BE
    Gene Ther; 2006 Oct; 13(20):1480-92. PubMed ID: 16738691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro.
    Lopalco L; Barassi C; Pastori C; Longhi R; Burastero SE; Tambussi G; Mazzotta F; Lazzarin A; Clerici M; Siccardi AG
    J Immunol; 2000 Mar; 164(6):3426-33. PubMed ID: 10706739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of immune responses and break of tolerance by DNA against the HIV-1 coreceptor CCR5 but no protection from SIVsm challenge.
    Zuber B; Hinkula J; Vödrös D; Lundholm P; Nilsson C; Mörner A; Levi M; Benthin R; Wahren B
    Virology; 2000 Dec; 278(2):400-11. PubMed ID: 11118363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo.
    Bai J; Gorantla S; Banda N; Cagnon L; Rossi J; Akkina R
    Mol Ther; 2000 Mar; 1(3):244-54. PubMed ID: 10933940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence as a HIV-1 self-defense vaccine of cyclic chimeric dodecapeptide warped from undecapeptidyl arch of extracellular loop 2 in both CCR5 and CXCR4.
    Misumi S; Takamune N; Ido Y; Hayashi S; Endo M; Mukai R; Tachibana K; Umeda M; Shoji S
    Biochem Biophys Res Commun; 2001 Aug; 285(5):1309-16. PubMed ID: 11478800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cyclic dodecapeptide-multiple-antigen peptide conjugate from the undecapeptidyl arch (from Arg(168) to Cys(178)) of extracellular loop 2 in CCR5 as a novel human immunodeficiency virus type 1 vaccine.
    Misumi S; Nakajima R; Takamune N; Shoji S
    J Virol; 2001 Dec; 75(23):11614-20. PubMed ID: 11689643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
    Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC
    J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of CCR5 on activated CD4 T cells in HIV-infected Indians.
    Dubey S; Khalid M; Wesley C; Khan SA; Wanchu A; Jameel S
    J Clin Virol; 2008 Sep; 43(1):25-31. PubMed ID: 18462992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast milk CD4+ T cells express high levels of C chemokine receptor 5 and CXC chemokine receptor 4 and are preserved in HIV-infected mothers receiving highly active antiretroviral therapy.
    Kourtis AP; Ibegbu CC; Theiler R; Xu YX; Bansil P; Jamieson DJ; Lindsay M; Butera S; Duerr A
    J Infect Dis; 2007 Apr; 195(7):965-72. PubMed ID: 17330786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction, purification, and immunogenicity of recombinant cystein-cystein type chemokine receptor 5 vaccine.
    Wu K; Xue X; Wang Z; Yan Z; Shi J; Han W; Zhang Y
    Protein Expr Purif; 2006 Sep; 49(1):108-13. PubMed ID: 16600624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-protection of individual CD4+ T cells against R5 HIV-1 infection by the synthesis of anti-viral CCR5 ligands.
    Guan Y; Abdelwahab S; Kamin-Lewis R; DeVico AL; Lewis GK
    PLoS One; 2008; 3(10):e3481. PubMed ID: 18941536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors.
    Cohen OJ; Vaccarezza M; Lam GK; Baird BF; Wildt K; Murphy PM; Zimmerman PA; Nutman TB; Fox CH; Hoover S; Adelsberger J; Baseler M; Arthos J; Davey RT; Dewar RL; Metcalf J; Schwartzentruber DJ; Orenstein JM; Buchbinder S; Saah AJ; Detels R; Phair J; Rinaldo C; Margolick JB; Pantaleo G; Fauci AS
    J Clin Invest; 1997 Sep; 100(6):1581-9. PubMed ID: 9294127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV neutralizing IgA in exposed seronegative subjects recognise an epitope within the gp41 coiled-coil pocket.
    Pastori C; Barassi C; Piconi S; Longhi R; Villa ML; Siccardi AG; Clerici M; Lopalco L
    J Biol Regul Homeost Agents; 2000; 14(1):15-21. PubMed ID: 10763886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of HIV-1 epitopes that induce the synthesis of a R5 HIV-1 suppression factor by human CD4+ T cells isolated from HIV-1 immunized hu-PBL SCID mice.
    Yoshida A; Tanaka R; Kodama A; Yamamoto N; Ansari AA; Tanaka Y
    Clin Dev Immunol; 2005 Dec; 12(4):235-42. PubMed ID: 16584108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR4 and CCR5 expression on CD4+ T cells in vivo and HIV-1 antigen beta-chemokine production in vitro after treatment with HIV-1 immunogen (REMUNE).
    Moss RB; Giermakowska WK; Diveley JP; Savary JR; Wallace MR; Maigetter RZ; Jensen FC; Carlo DJ
    J Hum Virol; 2000; 3(1):44-9. PubMed ID: 10774806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
    Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
    J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.